Clinical trial NCT06588660: ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Official title: Phase 1b Study of ST-067 (Decoy-Resistant IL-18) With Teclistamab in Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Lead sponsor: University of Washington
Sponsor class: OTHER
Collaborators: name: Simcha Therapeutics
First posted: 2024-09-19
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase Ib trial tests the safety, side effects and best dose of ST-067 in combination with teclistamab and how well it works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). ST-067 is an engineered variant of the human cytokine interleukin-18 that may help the immune system kill cancer cells. Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving ST-067 in combination with teclistamab may be safe, tolerable and/or effective in treating patients with relapsed or refractory multiple myeloma.

Detailed description: OUTLINE: This is a dose-escalation study of ST-067 in combination with teclistamab followed by a dose-expansion study.

Patients receive ST-067 subcutaneously (SC) on days 1, 8, 15 and 22 of cycle 1, on days 8, 15 and 22 of cycle 2, then on days 1 and 15 of subsequent cycles. Patients also receive teclistamab SC on days 1, 3, 5, 15 and 22 of cycle 2 then on days 1, 8, 15, and 22 or on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection throughout the trial and bone marrow aspiration and biopsy during screening and on study.

After completion of study treatment, patients are followed every 3 months for up to 5 years.

Eligibility criteria: Inclusion Criteria:

* Multiple myeloma, as defined by the presence of at least one International Myeloma Working Group (IMWG) MM-defining event
* Measurable disease as defined by IMWG criteria, requiring one or more of the following:

  * Serum M-protein ≥ 0.5 g/dL
  * Urine M-protein ≥ 200 mg/24h
  * Involved serum free light chain ratio ≥ 10 mg/dL with abnormal kappa/lambda ratio
  * Measurable plasmacytoma, defined as ≥ 1 lesion with cross-sectional diameter ≥ 2 centimeters)
  * Bone marrow plasma cell percentage ≥ 30%
* Eligibility to receive commercial tec per the Food and Drug Administration (FDA) package insert. This requires (1) at least 4 prior lines of therapy including a proteasome inhibitor (PI), immune modulatory imide drug (IMID), and CD38 monoclonal antibody (mAb); and (2) refractoriness, intolerance, or ineligibility (as deemed by the patient's treating physician) to other established therapies known to provide clinical benefit in MM

  * If the FDA package insert for tec is changed to allow for its use in earlier lines of therapy, the above-mentioned stipulations still apply until a protocol modification is approved
* Age ≥ 18 at study screening
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
* Anticipated survival of \> 3 months
* Estimated glomerular filtration rate (eGFR) ≥ 40 mL/min using the Modification of Diet in Renal Disease equation
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) both ≤ 3 x the lab's upper limit of normal (ULN)
* Total bilirubin ≤ 2 x ULN
* Platelets ≥ 25,000/μL at screening (no more than 1 transfusion in the 7-day period leading up to screening labs)
* Hemoglobin ≥ 7 g/dL at screening (no more than 1 transfusion in the 7-day period leading up to screening labs)
* Absolute neutrophil count (ANC) ≥ 1000 cells/mm\^3 at screening (no more than one administration of growth factor in the 7-day period leading up to screening labs)
* For patients of reproductive potential only: Willingness to use an effective contraceptive method before, during, and for at least 5 months after the last dose of study therapy
* Ability to understand and provide informed consent as well as willingness to comply with study requirements including visits and biopsies

Exclusion Criteria:

* History of prior BCMA-directed therapy in the past 12 months
* History of another primary malignancy that has not been in remission for at least 1 year

  * However, the following diagnoses are eligible for inclusion: non-melanoma skin cancer, localized prostate cancer, superficial bladder cancer, cervical carcinoma in situ, or any prior malignancy with an estimated \> 90% 1-year cure rate per sponsor-investigator
* Any condition requiring systemic treatment with corticosteroids (\> 10mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study drug administration. This includes active cytokine release syndrome (CRS), active graft-versus-host disease, or autoimmune conditions

  * Inhaled or topical steroids are allowed, as are replacement corticosteroids for adrenal insufficiency
* Concurrent use of other anti-MM agents, including investigational drugs, within 7 days of study screening
* Known central nervous system (CNS) involvement of MM at time of study screening
* Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at time of study screening
* Current pregnancy or breastfeeding, or planned pregnancy or breastfeeding within the next 12 months
* Corrected QT (QTc) interval (Bazett formula) ≥ 500 milliseconds on screening electrocardiogram (ECG)
* Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Primary outcomes:
measure: Monotherapy dose-limiting toxicities (DLT) rates
timeFrame: Up to 28 days (cycle 1)
measure: Combination therapy DLT rates
timeFrame: Up to 28 days (cycle 2)
measure: Optimal biological dose (OBD)
timeFrame: Up to 28 days
measure: Incidence of adverse events (AEs)
timeFrame: Up to 30 days after last dose of ST-067
Secondary outcomes:
measure: Overall response rate (ORR)
timeFrame: At months 1 and 3
measure: Minimal residual disease (MRD) negativity
timeFrame: At 1 month after initiation of teclistamab
measure: Duration of response (DOR)
timeFrame: Up to 5 years
measure: Progression-free survival (PFS)
timeFrame: From first dose of teclistamab to disease progression or death up to 5 years
measure: Overall survival (OS)
timeFrame: From first dose of teclistamab to death up to 5 years
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Fred Hutch/University of Washington Cancer Consortium
state: Washington
Study officials:
affiliation: Fred Hutch/University of Washington Cancer Consortium
name: Rahul Banerjee, MD
role: PRINCIPAL_INVESTIGATOR
References: